Fragility Fractures of the Pelvis (FFP)

NCT ID: NCT04182776

Last Updated: 2025-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

420 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-03-01

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prospective data will be collected in approximately 420 patients, above the age of 65, suffering from an FFP type fracture equal to or higher than type II, according to Rommens and Hofmann.

Patients will be followed up according to the standard (routine) for up to 1 year after the treatment. Data collection will include underlying disease, treatment details, functional and patient reported outcomes (PRO)s, radiological outcomes, and anticipated or procedure-related adverse events (i.e. complications).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

More in detail this registry has the following objectives:

* To identify the difference in patient related outcome comparing the surgical and conservative treatment in patients suffering from an FFP with different levels of pelvic instability at different time points
* To compare the rate of complications, morbidity and mortality between the different treatment modalities over the whole study period

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pelvic Fracture

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Pelvis Fragility Fracture Classification Conservative Operative

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pelvis fracture type II to IV

All treatments will remain the standard (routine) care procedures based on individual clinician's judgment and the patient characteristics. The registry does not dictate any specific treatment.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 65 years or older at time of injury
* Diagnosis, via CT scan as per standard of care, of FFP grade II or higher according to the Rommens and Hofmann classification (including fractures of the anterior pelvic ring involving the anterior lip of the acetabulum not regarded as the acetabular fractures)
* Informed consent obtained, ie:

* Ability to understand the content of the patient information/ICF
* Willingness and ability to participate in the registry according to the standard of care in each clinic
* Signed and dated Ethics Committee (EC)/ Institutional Review Board (IRB) approved written informed consent OR
* Written consent provided according to the IRB/EC defined and approved procedures for patients who are not able to provide independent written informed consent

Exclusion Criteria

* Pelvic fractures that do not meet the criteria of a fragility fracture (ie, high-energy trauma)
* FFP type I fractures
* Concomitant fractures of the acetabulum (except anterior lip of the acetabulum, see above)
* Pathological fractures (ie, patients with malignant or metastatic diseases of the pelvis, infections)
* Concomitant osteoporotic fractures outside of pelvis
* Participation in any other medical device or medicinal product study within the previous month that could influence in opinion of the PI the results of the present registry
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AO Innovation Translation Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pol Maria Rommens, MD

Role: PRINCIPAL_INVESTIGATOR

University Medical Center Johannes Gutenberg-University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Missouri

Columbia, Missouri, United States

Site Status RECRUITING

The Ottawa Hospital - Civic Campus

Ottawa, , Canada

Site Status RECRUITING

University Medical Center Hamburg Eppendorf

Hamburg, , Germany

Site Status RECRUITING

University Hospital Leipzig

Leipzig, , Germany

Site Status RECRUITING

University Medical Center Johannes Gutenberg-University

Mainz, , Germany

Site Status RECRUITING

Queen Mary Hospital

Hong Kong, , Hong Kong

Site Status RECRUITING

Okayama medical hospital

Okayama, , Japan

Site Status RECRUITING

University Medical Center Groningen

Groningen, , Netherlands

Site Status RECRUITING

Radboud University Medical Center

Nijmegen, , Netherlands

Site Status TERMINATED

Cantonal Hospital Lucerne

Lucerne, , Switzerland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Germany Hong Kong Japan Netherlands Switzerland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Aleksandra Hodor

Role: CONTACT

Phone: +41442002481

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Gregory Della Rocca

Role: primary

Geoffrey Wilkin

Role: primary

Maximilian Hartel

Role: primary

Philipp Pieroh

Role: primary

Pol Maria Rommens, MD

Role: primary

Daniel Wagners, MD

Role: backup

King Hang Dennis Yee

Role: primary

Naofumi Shiota

Role: primary

Frank IJpma

Role: primary

Matthias Knobe

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AOFFP

Identifier Type: -

Identifier Source: org_study_id